Fiche publication
Date publication
septembre 2016
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr THIERY-VUILLEMIN Antoine
Tous les auteurs :
Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, Bögemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Houédé N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi K
Lien Pubmed
Résumé
Cabozantinib is an inhibitor of kinases, including MET and vascular endothelial growth factor receptors, and has shown activity in men with previously treated metastatic castration-resistant prostate cancer (mCRPC). This blinded phase III trial compared cabozantinib with prednisone in patients with mCRPC.
Mots clés
Adult, Aged, Aged, 80 and over, Anilides, adverse effects, Antineoplastic Agents, adverse effects, Biomarkers, Tumor, metabolism, Disease-Free Survival, Double-Blind Method, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplastic Cells, Circulating, pathology, Prednisone, adverse effects, Prostatic Neoplasms, Castration-Resistant, drug therapy, Protein Kinase Inhibitors, adverse effects, Pyridines, adverse effects, Survival Rate
Référence
J. Clin. Oncol.. 2016 Sep 1;34(25):3005-13
